Executive Officer

Susan Goodin - 150pxSusan Goodin, PharmD, is executive director of statewide affairs at Rutgers Cancer Institute of New Jersey and professor of medicine at Rutgers Robert Wood Johnson Medical School. She possesses more than 20 years of clinical research leadership experience including serving as the deputy director of operations, associate director of clinical trials and therapeutics, and director of the Division of Pharmaceutical Sciences at the Cancer Institute of New Jersey. She played a key role in the establishment of the Cancer Institute’s clinical practice and designed its clinical research infrastructure, including the Center’s research office, research pharmacy, and protocol review and monitoring system and is a founding co-leader of the Cancer Institute of New Jersey’s statewide clinical trials network that includes 15 hospitals under the Center’s clinical research infrastructure.

As executive officer of the Big Ten CRC, Dr. Goodin works closely with administrative headquarters, pharmaceutical partners, and other physicians and researchers to carry out the consortium’s mission. She serves as the primary spokesperson and representative for the consortium at meetings and events with funders and professional organizations, and communicates regularly with Big Ten CRC cancer center directors and the steering committee regarding key issues, challenges, and opportunities facing the consortium.

Steering Committee

The Big Ten CRC Steering Committee is composed of one researcher from each member institution. The Steering Committee meets on a regular basis to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC.

Members of the Steering Committee include: